ADAR1 Capital Management’s NewAmsterdam Pharma NAMS Stock Holding History

ADAR1 Capital Management’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.02M	Hold	118,623	–	–	0.18%	111
2026 Q1	$3.8M	Hold	118,623	–	–	0.22%	92
2025 Q4	$4.16M	Buy	118,623 +4,264	+4%	+$155K	0.31%	66
2025 Q3	$3.25M	Buy	114,359 +2,000	+2%	+$47.9K	0.31%	60
2025 Q2	$2.03M	Buy	+112,359	New	+$2.05M	0.31%	54

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

ADAR1 Capital Management's NAMS Position: Q2 2026 in Review

ADAR1 Capital Management held its NewAmsterdam Pharma (NAMS) position steady in Q2 2026 at 118,623 shares worth $4.02M. The position accounts for 0.18% of the portfolio, ranked #111.

ADAR1 Capital Management first reported a position in NAMS in Q2 2025 and has held it in 5 quarters since. The position peaked at $4.16M in Q4 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

ADAR1 Capital Management held 118,623 shares of NewAmsterdam Pharma worth $4.02M as of Q2 2026.
ADAR1 Capital Management left its NewAmsterdam Pharma share count unchanged in Q2 2026.
NewAmsterdam Pharma made up 0.18% of ADAR1 Capital Management's portfolio in Q2 2026, its #111 holding.
ADAR1 Capital Management first reported a position in NewAmsterdam Pharma in Q2 2025 and has held it in 5 quarters since.
ADAR1 Capital Management's NewAmsterdam Pharma position peaked at $4.16M in Q4 2025.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.